Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Study sponsor: aTyr Pharma, Inc. · ATYR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-04Estimated
Enrollment · participants25Estimated
Source updated2025-05-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.